Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility | MicrobiomeTrials← Back to trialsNCT04244877
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
WITHDRAWNPHASE3INTERVENTIONAL
Trial Details
Start: 2021-09-15Est. Completion: 2023-05-01
Enrollment target: 0 participants Other microbiome trials you might be interested in
Hematopoietic Stem Cell Transplant
Background:
Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But m…
Bethesda, United StatesEst. completion Jun 30, 2031
Liver CirrhosisDecompensated Cirrhosis of Liver
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health o…
Clichy, FranceCompleted Jul 1, 2026
Cirrhosis, LiverSplenectomy; StatusRenal Function AbnormalPortal Hypertension
Patients with liver cirrhosis and portal hypertension often have impaired kidney function due to reduced blood flow to t…
Multiple LocationsCompleted Feb 2026